A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)

NCT01713582 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Diffuse Large B-cell Lymphoma
Acute Lymphoblastic Leukemia
Multiple Myeloma

Interventions

DRUG: OTX015/Birabresib

Sponsor

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)